Biomarin Pharmaceutical Inc (BMRN)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 2,845,320 | 2,374,190 | 2,068,670 | 1,832,750 | 1,823,140 |
| Receivables | US$ in thousands | 660,535 | 633,704 | 461,316 | 373,399 | 448,351 |
| Receivables turnover | 4.31 | 3.75 | 4.48 | 4.91 | 4.07 |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $2,845,320K ÷ $660,535K
= 4.31
The receivables turnover ratio of Biomarin Pharmaceutical Inc has shown some fluctuations over the past five years. The ratio increased from 4.07 in December 31, 2020, to 4.91 in December 31, 2021, indicating that the company collected its accounts receivable more efficiently in 2021. However, it then decreased to 4.48 in December 31, 2022, suggesting a slight slowdown in receivables turnover.
In December 31, 2023, the receivables turnover dropped further to 3.75, which may indicate a longer collection period for the company's receivables. However, there was a recovery in December 31, 2024, where the ratio increased to 4.31, showing an improvement in collecting outstanding receivables compared to the previous year.
Overall, Biomarin Pharmaceutical Inc's receivables turnover ratio has exhibited some variability in the past five years, with fluctuations that could be due to changes in the company's credit policies, customer payment behaviors, or economic conditions impacting the industry.
Peer comparison
Dec 31, 2024